Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather H Cheng

Showing results (81-90 of 141) with videos related to

Pageof 15
Sort By:
Prostate Cancer and Prostatic Diseases|December 23, 2022
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancerMichael T Schweizer, Roman Gulati, Todd Yezefski, et al.
The Journal of Urology|February 29, 2024
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical ProstatectomyTodd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, et al.
Clinical Genitourinary Cancer|January 29, 2023
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder CancerDimitrios Makrakis, Jonathan L Wright, Martine P Roudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate CancerEvan Y Yu, Hongli Li, Celestia S Higano, et al.
The Journal of Urology|February 29, 2024
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future DirectionsTodd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, et al.
The Journal of Urology|February 29, 2024
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical ProstatectomyTodd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, et al.
JCI Insight|May 31, 2019
Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsyBrian R Winters, Navonil De Sarkar, Sonali Arora, et al.
The Prostate|September 13, 2021
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutationsAlexandra O Sokolova, Catherine H Marshall, Rebeca Lozano, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 6, 2023
Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the USEmily M Rencsok, Natalie Slopen, Karen Autio, et al.
JCO Precision Oncology|May 25, 2019
Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene MutationsMichael T Schweizer, Emmanuel S Antonarakis, Tarek A Bismar, et al.
Pageof 15

Showing results (81-90 of 141) with videos related to

Sort By:
Pageof 15
Prostate Cancer and Prostatic Diseases|December 23, 2022
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancerMichael T Schweizer, Roman Gulati, Todd Yezefski, et al.
The Journal of Urology|February 29, 2024
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical ProstatectomyTodd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, et al.
Clinical Genitourinary Cancer|January 29, 2023
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder CancerDimitrios Makrakis, Jonathan L Wright, Martine P Roudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate CancerEvan Y Yu, Hongli Li, Celestia S Higano, et al.
The Journal of Urology|February 29, 2024
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future DirectionsTodd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, et al.
The Journal of Urology|February 29, 2024
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical ProstatectomyTodd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, et al.
JCI Insight|May 31, 2019
Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsyBrian R Winters, Navonil De Sarkar, Sonali Arora, et al.
The Prostate|September 13, 2021
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutationsAlexandra O Sokolova, Catherine H Marshall, Rebeca Lozano, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 6, 2023
Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the USEmily M Rencsok, Natalie Slopen, Karen Autio, et al.
JCO Precision Oncology|May 25, 2019
Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene MutationsMichael T Schweizer, Emmanuel S Antonarakis, Tarek A Bismar, et al.
Pageof 15